Topics:

New Opioid Pain Reliever Approved With Required Risk-Reduction Plan

New Opioid Pain Reliever Approved With Required Risk-Reduction Plan

The US Food and Drug Administration recently approved fentanyl buccal soluble film (Onsolis), a medication intended for certain patients with cancer to help manage breakthrough pain.

Onsolis delivers fentanyl via an absorbable film that sticks to the inside of the cheek. The drug is indicated for the management of breakthrough pain in patients with cancer, ages 18 and older, who already use opioid pain medication around the clock and who need and are able to safely use high doses of an additional opioid medicine. Such patients are considered opioid tolerant because of their current opioid medication use.

Because fentanyl is subject to abuse and misuse, Onsolis was approved with a Risk Evaluation and Mitigation Strategy, or REMS, which is a required plan for managing risks associated with a drug or biological product.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.